How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lenacapavir-long-acting.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Lenacapavir long-acting — Competitive Intelligence Brief

Lenacapavir long-acting (Lenacapavir long-acting) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV capsid inhibitor. Area: Infectious Disease.

marketed HIV capsid inhibitor HIV capsid protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Lenacapavir long-acting (Lenacapavir long-acting) — ViiV Healthcare. Lenacapavir is a first-in-class HIV capsid inhibitor that binds to the HIV capsid protein and blocks the uncoating of viral RNA, preventing early steps of HIV replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lenacapavir long-acting TARGET	Lenacapavir long-acting	ViiV Healthcare	marketed	HIV capsid inhibitor	HIV capsid protein
Lenacapavir Injection	Lenacapavir Injection	Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida	phase 3	HIV capsid inhibitor	HIV capsid protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV capsid inhibitor class)

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · 1 drug in this class
ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenacapavir long-acting — Competitive Intelligence Brief. https://druglandscape.com/ci/lenacapavir-long-acting. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab